Clinical Research Directory
Browse clinical research sites, groups, and studies.
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Sponsor: The First Affiliated Hospital of Zhengzhou University
Summary
Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics, ultimately impacting treatment efficacy and patient survival. Glutathione, a critical bioactive molecule, demonstrates broad potential in tumor immunotherapy. Through mechanisms such as scavenging free radicals, modulating immune cell proliferation and differentiation, and regulating cytokine expression, glutathione achieves precise modulation of immune responses to enhance immune system functionality. To investigate whether glutathione can enhance the clinical efficacy of current chemo-immunotherapy regimens in non-small cell lung cancer (NSCLC), investigators conducted this clinical study.
Official title: Prospective, Randomized Controlled Clinical Trial of Glutathione Combined With PD-1 Antibody and Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-06-01
Completion Date
2027-12-31
Last Updated
2025-08-07
Healthy Volunteers
No
Interventions
Glutathione
Glutathione is administered as an adjunct intervention to the PD-1 inhibitor plus chemotherapy regimen.
PD1 Inhibitor
e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab
Chemotherapy
Platinum-based doublet chemotherapy
Locations (1)
the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China